All News

June, 2024

CEO. Dr. Hanadie Yousef participates in AFAR’s webinar on AI + Longevity Drug DiscoveryLearn More »

June, 2024

CEO Dr. Hanadie Yousef gives a talk on Juvena’s AI-enabled protein drug discovery and development platform and lead therapeutic candidates for muscle regeneration and enhancing fat metabolism at the Longevity Summit DublinLearn More »

June, 2024

CEO Dr. Hanadie Yousef represents Juvena on 2 panels at BIO San Diego to discuss navigating the frontiers of First-in-Class therapeutics, and how healthspan promoting therapeutics are entering the biopharma mainstream.Learn More »

June, 2024

Juvena is selected by the World Economic Forum to join its 2024 global cohort of Technology Pioneers, awarded to the 100 most innovative tech startups applying new breakthroughs in AI to solve some of the biggest challenges of our time.Learn More »

June, 2024

Dr. Jeremy O’Connell, Director of translation Dr. Priya Handa, and Scientist Dr. Ritwik Datta attend and present our latest results at ENDO 2024, highlighting how  JUV-112 Offers a Distinctive Approach to Weight Loss and Metabolic HealthLearn More »

June, 2024

Juvena’s SVP of Translation, Dr. Mo Tabrizi participates in the Seattle Myotonic Dystrophy Regional Summit, where Juvena gave an industry presentation.Learn More »

May, 2024

Juvena’s CEO Dr. Hanadie Yousef participates in the LA Myotonic Dystrophy Regional Summit, where Juvena gave an industry presentation.Learn More »

May, 2024

Juvena’s Director of Discovery & Platform, Dr. Thach Mai presents “Mapping the therapeutic potential of secreted proteins through integrating AI and quantitative multi-omics technology” at the Element Biosciences RoadshowLearn More »

May, 2024

InVivo spotlights CEO and Co-Founder Dr. Hanadie Yousef’s Journey with Juvena TherapeuticsLearn More »

April, 2024

Jeremy O’Connell presents video discussing JUV-161 for myotonic dystrophy type 1 (DM1)Learn More »

April, 2024

CEO and co-Founder Dr. Hanadie Yousef recognized as In Vivo’s 2024 Rising Leaders, which includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.Learn More »

April, 2024

One of In Vivo’s 2024 Rising Leaders, Dr. Hanadie Yousef, CEO of Juvena Therapeutics, talks about the secretome as a source of therapeutics, the company’s lead assets, the future of longevity medicine and learning as you go as a biotech entrepreneur.Learn More »

March, 2024

Juvena’s CMO Dr. Barney King participates in the Myotonic Dystrophy Regional Summit, where Juvena gave an industry presentation.Learn More »

March, 2024

CEO Dr. Hanadie Yousef participates in a panel on “Demystifying Aging” at Horizons Ventures 2024 Techcracker summit Learn More »

March, 2024

Juvena CEO and CO-Founder Dr. Hanadie Yousef featured in San Francisco Business Times article highlighting women biotech leadersLearn More »

March, 2024

Ashil Koranne presented a poster at the 2024 MDA Clinical & Scientific Conference highlighting Juvena Therapeutics’ promising preclinical development of JUV-161, a novel fusion protein for treating Myotonic Dystrophy Type 1.Learn More »

March, 2024

Juvena recognized by The Wall Street Journal for developing regenerative therapies aimed at weight loss and prevention of muscle wastingLearn More »

January, 2024

Juvena gets FDA Orphan Drug nod for muscle regeneration therapyLearn More »

January, 2024

Juvena’s JUV-161 named FDA orphan drug for DM1Learn More »

January, 2024

Juvena’s JUV-161 awarded US orphan drug designation for myotonic dystrophy type 1Learn More »

January, 2024

Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1Learn More »

January, 2024

Juvena Therapeutics is recognized in Biospace’s Top 30 list, “NextGen Class of 2024: Top Life Sciences Startups to Watch This Year”Learn More »

January, 2024

CEO Dr. Yousef speaks about “The Science of Longevity: Stopping Aging at the Cellular Level to Prevent Disease and Improve Quality of Life” as an invited panelist for the 2023 Biotech Showcase.Learn More »

November, 2023

Juvena’s CEO, Dr. Hanadie Yousef is recognized by FierceBiotech in their 2023 shortlist of 10 of the fiercest women in life sciences.Learn More »

November, 2023

CEO Dr. Hanadie Yousef discussed the convergence of AI, healthcare, and longevity in early November in Paris at JPM 40×40 as an invited speaker amongst a curated group of global business leaders across all sectors.Learn More »

November, 2023

Dr. Hanadie Yousef attends the Global Healthspan Summit in Riyadh, Saudi Arabia, organized by the Hevolution Summit as an invited speaker showcased on their Entrepreneurship Spotlight panelLearn More »

October, 2023

CEO, Dr. Yousef presented Juvena’s approach to mining the regenerative secretomes of human pluripotent stem cells to identify and develop novel disease-modifying biologics that promote tissue regeneration and repair in order to rejuvenate lives as the 14th annual drug discovery strategic summit this year.Learn More »

October, 2023

Congratulations to our outstanding ML Engineer, Tejaswini Ganapathi for presenting a poster based on her AI research at Juvena entitled “Prediction of transcriptomic response to perturbagens in unobserved cell lines and cell states” at the ML Drug Discovery Symposium at Broad Institute of MIT and Harvard on October 27, 2023. We presented our exciting development of a generalized machine learning system that predicts biological effects such as gene expression changes on cells.Learn More »

October, 2023

Congratulations to Juvena Therapeutics Co-Founder and CEO Dr. Yousef for being named a “Big Think” speaker at #BioFuture2023 in recognition of the company’s accelerated growth and momentum in addressing a long-standing critical gap in drug discovery by unlocking the therapeutic potential of secreted proteins in order to develop regenerative therapeutics.Learn More »

September, 2023

Our Director of Discovery and Platform, Dr. Thach Mai and CSO Dr. Jeremy O’Connell share more about Juvena’s discovery platform and approach to identifying and developing a regenerative biologics for promoting lung epithelium re-growth for the treatment of idiopathic pulmonary fibrosis at the IPF 2023 Annual summit.Learn More »

September, 2023

Juvena is delighted to have had the opportunity to participate in the Mubadala Capital Singapore Forum. CEO Dr. Yousef was on the panel, “The New Frontier of Biotech Investing & Company Creation”Learn More »

September, 2023

Juvena’s CSO, Dr. Jeremy O’Connell, and VP Dr. Mo Tabrizi attend and present our DM1 lead program at the annual Myotonic Dystrophy Foundation Conference which we are proud to sponsorLearn More »

September, 2023

National Institute on Aging Spotlights our CEO’s scientific journey and Juvena Therapeutics mission to unlock the secrets of tissue regenerationLearn More »

August, 2023

CEO Dr. Hanadie Yousef is recognized by Business Insider on their shortlist of 30 under 40 Transforming Healthcare Learn More »

August, 2023

EARD 2023 Panel, “Is Aging Truly Reversible” Featuring CEO Dr. Hanadie YousefLearn More »

July, 2023

Excited to announce Juvena’s CEO, Dr. Yousef’s participation at the Longevity Summit: Ending Age-Related Diseases in NYC on August 10-11! Join her and other experts as we revolutionize the field of aging research. Learn more and register hereLearn More »

July, 2023

Wu Xi Apptec spotlights Juvena Therapeutics on their Spotlight III: “The Next Wave of Rare Disease Therapeutics” episode. Our CEO, Dr. Yousef discusses Juvena’s unique approach to developing innovative disease-modifying biologics for chronic and rare degenerative diseases by mapping the therapeutic potential of secreted proteins. Learn more and register for the July 27 episode here.Learn More »

June, 2023

The Juvena team made a big splash at the 5th Age-Related Disease Therapeutics Summit in San Francisco! CEO, Dr. Hanadie Yousef gave a well received talk on mapping secreted proteins to unmet medical needs, as well as moderating the session of impressive speakers focused on biomarkers for age-related and chronic diseases. Juvena’s VP of Data Science, Dr. Eddie Moler co-led a pre-conference workshop on exploring the promise of AI-Powered drug discovery for the progression of age-related therapies, while Computational Biologist, Dr. Rohit Jadhav presented a poster on Juvena’s proteomics platform for mining the secretomes of stem cells. Learn More »

June, 2023

Discovery of Biologic Therapeutics in the AI/ML Era: 20-year industry veteran and Vice President of Data Science, Dr. Edward Moler, PhD, shares his insights on navigating AI-driven discoveries with high therapeutic potentialLearn More »

May, 2023

Check out the Pharma Exec Podcast of CEO Dr. Hanadie Yousef’s interview for the Emerging Pharma Leader award to learn more about what drives her ambitions for JuvenaLearn More »

May, 2023

Endpoints: CEO and co-Founder Dr. Hanadie Yousef is recognized by Endpoints for her lifelong scientific work and discoveries, for her entrepreneurship and business leadership as part of the 2023 “20 under 40” list of exceptional biotech leaders and global change makersLearn More »

May, 2023

Juvena’s CEO and co-founder, Dr. Hanadie Yousef, was named among a distinguished short list of Emerging Pharma Leaders by Pharmaceutical Executive, which highlights her personal story and what drives Dr. Yousef’s passion for decoding secreted proteins for better human healthLearn More »

March, 2023

CEO Dr. Yousef joins the Biotech CEO sisterhood summit to cultivate a community of support for female-led biotech companies and mentorship. Discussions included CEO best practices, wellness, supporting women leaders, and board service.  Learn more here where she is quoted.Learn More »

January, 2023

Biocom highlights backgrounds of Catalyst Award winners including CEO Hanadie YousefLearn More »

January, 2023

As Juvena continues to welcome a tremendously talented team, we wanted to thank FierceBiotech, Endpoints News, STAT, Longevity.Technology, BioWorld, and BioCentury for highlighting Juvena Therapeutics’ expanded leadership team last week. Juvena is thrilled to have Neil Berkley as Chief corporate development officer, Mo Tabrizi PhD, RPh as VP of preclinical and non-clinical development, and Edward Moler, PhD as VP of data science. Juvena is looking forward to what’s ahead!Learn More »

January, 2023

BioWorld Features Dr. Yousef’s and Dr. O’Connell’s founding story, showcasing Juvena’s proteomics platform to tackle chronic and age-related diseases by mining hESC-secreted proteinsLearn More »

January, 2023

Juvena Therapeutics Bolsters Leadership Team With Key Industry Veterans in Drug Discovery and Development, Data Science, and Business DevelopmentLearn More »

January, 2023

Juvena’s Head of Data Science, Dr. Eddie Moler interviewed about his experiences in data science and AI applied to diagnostics and drug discovery and shares why he is excited about JuvenaLearn More »

January, 2023

National Institute of Aging showcases Juvena TherapeuticsLearn More »

December, 2022

Longevity Technology Spotlights the Early Beginnings and Future Vision of Juvena TherapeuticsLearn More »

December, 2022

Juvena’a CEO, Dr. Hanadie Yousef discusses “Harnessing the Regenerative Secretome of Human Pluripotent Stem Cells” with other industry leaders discussing key areas of innovation advancing human healthspan and longevity at the Second Annual Longevity SummitLearn More »

November, 2022

Juvena’s lead drug discovery Scientist, Dr. Thach Mai, gave an excellent lecture, “Mapping Secreted Proteins to Unmet Medical Needs” to graduate students at Maastricht Centre for Systems Biology (MaCSBio).  Dr. Mai outlined Juvena’s use of machine learning and computational tools to unravel the therapeutic potential of stem cell-secreted human proteinsLearn More »

November, 2022

Stanford University welcomed CEO Dr. Hanadie Yousef as a guest lecturer to share her journey in launching Juvena TherapeuticsLearn More »

November, 2022

Juvena CEO, Hanadie Yousef, Explores the Future of the Intersection of Technology and Biology Alongside Silicon Valley Entrepreneurs with Middle East & Northern African roots at the Annual TechWadi ForumLearn More »

November, 2022

Biocom California Names Juvena CEO Hanadie Yousef as One of Ten Recipients of Its 7th Annual Catalyst Award, Recognizing the Most Inspiring and Driven Minds Sparking Meaningful Change to Human HealthLearn More »

November, 2022

The Wall Street Journal Discusses Juvena’s Series A and Its Potential to Expand the Range of Treatments for Chronic Conditions and Disease of AgingLearn More »

November, 2022

Juvena Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related DiseasesLearn More »

November, 2022

Discussing longevity insights among financial and biotech leaders at the BioFuture Conference, Juvena CEO, Hanadie Yousef, PhD explores the role of secreted proteins in targeting chronic and age-related diseases.Learn More »

November, 2022

Juvena’s CSO, Dr. O’Connell, was an invited speaker at the 6th Annual Fibrotic Drug Discovery Summit in Nov. 2022 and discussed how decoding stem cell secreted proteins can enable drug discovery for fibrotic degenerative diseases, providing an overview of Juvena’s pulmonary and hepatic programs.Learn More »

November, 2022

Annual BioFuture 2022 Event Recognizes Juvena CEO Dr. Hanadie Yousef Among Longevity Pioneers Shaping Expectations in Healthcare and Celebrates the Company’s Series A AnnouncementLearn More »

November, 2022

Juvena Therapeutics is recognized for its transformative science that targets unmet medical needs as well as for the quality of its management team as part of the Emerging Company Showcase at the prestigious Life Sciences Summit.Learn More »

October, 2022

BioCom California, the leading life science industry organization in California recognizes Juvena’s CEO, Dr. Hanadie Yousef for her achievements, vision and scientific and business accumen in its Life Science Catalyst Awards.Learn More »

October, 2022

Juvena CEO, Hanadie Yousef, PhD, discusses the market opportunity for their unique discovery platform for mapping secreted proteins to unmet medical needs leading to their growing pipeline of biologics for rare and chronic diseases to senior leaders of Mubadala’s LP.Learn More »

October, 2022

To help drive change in biotech, Dr. Hanadie Yousef joined the industry’s leading women CEOs and investors at  the first joint Women Investors and CEOs networking event hosted by Sofinnova Investments and Cowen. Together these women are driven to create positive change in the industry, improving diversity among biotech c-suite and investors and supporting one another.Learn More »

September, 2022

Horizon Ventures Techcracker conference spotlights Juvena Co-Founder, Hanadie Yousef, PhD as one of 70 founders of innovative new companies developing disruptive technologies that improve lives Oct. 2022Learn More »

September, 2022

At the Myotonic Dystrophy Foundation Annual conference Juvena Therapeutics joins a community of advocates, people who suffer from this most common muscular dystrophy, their families, caregivers, clinical leaders and experts, and Industry leaders developing therapeutics for this major unmet medical need Sept. 2022Learn More »

August, 2022

The Ending Age-Related Diseases Conference Featured Juvena CEO and CO-Founder, Hanadie Yousef, PhD, as a leading aging biology expert discussing “Building a Pipeline of Therapeutics that Target Diseases of Aging” and Dr. Thach Mai, leading Discovery Scientist, discussing Juvena’s innovative ML-enhanced platform for protein drug discovery Aug. 2022Learn More »

August, 2022

EARD 2022: Mapping Secreted Proteins to Unmet Medical Needs by Dr. Thach Mai at Juvena August 2022Learn More »

July, 2022

CSO and Co-Founder Dr. Jeremy O’Connell presents at FASEB Industry Panel Jul. 2022Learn More »

June, 2022

CEO Hanadie Yousef was honored to represent Juvena Therapeutics at BIO International Convention in June 2022, where she gave a Company Presentation at the emerging company showcase. She had numerous meetings with exciting companies and investors focused on partnerships and was all around inspired by the exceptional attendees, sponsors, and organizers. Thanks to The National Institutes of Health for sponsoring the Innovation Zone and Juvena’s attendanceLearn More »

February, 2022

Juvena Therapeutics Awarded Highly Competitive 3.9M CIRM TRAN1 Grant to Advance Lead Program, JUV-161, to Treat Myotonic Dystrophy Type 1Learn More »

Hanadie-served-on-a-CEO-panel-with-a-group-of-portfolio-companies-for-Bascom-Ventures--thumbs

December, 2021

Hanadie served on a CEO panel with a group of portfolio companies for Bascom Ventures (part of Alumni Ventures)Learn More »

November, 2021

CIRM Awards Juvena a $3.9M TRAN1 Grant to Advance JUV-161 for Myotonic Dystrophy Type 1 (DM1)Learn More »

CEO-Dr.-Yousef-Represents-Juvena-at-Longevity-Summit-2021-Thumb

November, 2021

CEO Dr. Yousef Represents Juvena at Longevity Summit 2021Learn More »

CEO-Dr.-Yousef-Represents-Juvena-at-Metabesity-2021-thumb

October, 2021

CEO Dr. Yousef Represents Juvena at Metabesity 2021Learn More »

CEO-Dr.-Hanadie-Yousef-Interviewed-for-Translating-Aging-PodcastThe-Cures-Within-Us-thumb

August, 2021

CEO Dr. Hanadie Yousef Interviewed for Translating Aging Podcast, “The Cures Within Us”Learn More »

August, 2021

CEO Dr. Hanadie Yousef is interviewed by Ira Pastor for his Progress, Potential, and Possibilities show on Juvena’s development of Secretome Derived TherapiesLearn More »

Juvena-Therapeutics-Presents-at-the-Muscular-Dystrophy-Association-Insights-in-Research-Investor-Summit-thumb

April, 2021

Juvena Therapeutics Presents at the Muscular Dystrophy Association Insights in Research Investor SummitLearn More »

Juvena-Therapeutics-Interviewed-by-Fortune-Jan.-2021-thumb

February, 2021

Juvena Therapeutics Interviewed by Fortune Jan. 2021Learn More »

Juvena-Therapeutics-Presents-at-the-International-Longevity-Alliance-Conference-Workshop-Feb-2021-thumb

February, 2021

Juvena Therapeutics Presents at the International Longevity Alliance Conference Workshop Feb 2021Learn More »

Juvena-Therapeutics-at-Metabesity-Oct-2020-Conference-thumb

October, 2020

Juvena Therapeutics at Metabesity Oct 2020 ConferenceLearn More »

Ending-Age-Related-Diseases-Conference-August-2020-thumb

August, 2020

Ending Age-Related Diseases Conference August 2020Learn More »

March, 2020

CEO Hanadie Yousef Publishes in Cell ReportsLearn More »

February, 2020

Juvena Therapeutics Interviewed– Embryonic Proteins for Tissue Regeneration- Jan 2020Learn More »

January, 2020

Co-founders, Dr. Hanadie Yousef and Dr. Jeremy O’Connell were invited speakers at the 2nd Annual Longevity Conference in SF. While Yousef gave an oral presentation, O’Connell presented a poster about Juvena’s quantitative proteomics approach for mining the secretome of human pluripotent stem cells.Learn More »

January, 2020

Juvena Therapeutics Listed as 1 of 3 Ground Breaking Longevity StartupsLearn More »

November, 2019

CEO Dr. Hanadie Yousef Presents at UC Berkeley’s Slam Seminar Series Nov. 2019Learn More »

October, 2019

Dr. Hanadie Yousef’s Entrepreneurship Recognized by Spark at StanfordLearn More »

July, 2019

CEO Hanadie Yousef’s Nature Paper Featured in Science Signaling as Editors ChoiceLearn More »

May, 2019

CEO Hanadie Yousef’s Most Recent Publication in Nature MedicineLearn More »

March, 2019

Medium Blog Parameter Mentions Juvena TherapeuticsLearn More »

March, 2019

Juvena Therapeutics Mentioned in ForbesLearn More »

July, 2018

Juvena Therapeutics Mentioned in Middle Market GrowthLearn More »

January, 2017

Antibody Can Protect Brains From the Ageing Effects of Old BloodLearn More »

July, 2016

Hanadie Yousef, Cofounder and CEO, in Scope by Stanford MedicineLearn More »

May, 2016

The Bloody Battle Against AgingLearn More »

June, 2015

Featured in Vice: Engineering the End of AgingLearn More »

May, 2015

CEO Highlighted in the Daily CalifornianLearn More »

Press Releases & News Articles

June, 2024

Juvena is selected by the World Economic Forum to join its 2024 global cohort of Technology Pioneers, awarded to the 100 most innovative tech startups applying new breakthroughs in AI to solve some of the biggest challenges of our time.Read More »

April, 2024

CEO and co-Founder Dr. Hanadie Yousef recognized as In Vivo’s 2024 Rising Leaders, which includes entrepreneurs and innovators from across the world who represent the next wave of creativity in health care.Read More »

March, 2024

Juvena’s CMO Dr. Barney King participates in the Myotonic Dystrophy Regional Summit, where Juvena gave an industry presentation.Read More »

March, 2024

CEO Dr. Hanadie Yousef participates in a panel on “Demystifying Aging” at Horizons Ventures 2024 Techcracker summit Read More »

March, 2024

Juvena CEO and CO-Founder Dr. Hanadie Yousef featured in San Francisco Business Times article highlighting women biotech leadersRead More »

March, 2024

Juvena recognized by The Wall Street Journal for developing regenerative therapies aimed at weight loss and prevention of muscle wastingRead More »

January, 2024

Juvena gets FDA Orphan Drug nod for muscle regeneration therapyRead More »

January, 2024

Juvena’s JUV-161 named FDA orphan drug for DM1Read More »

January, 2024

Juvena’s JUV-161 awarded US orphan drug designation for myotonic dystrophy type 1Read More »

January, 2024

Juvena Therapeutics Receives FDA Orphan Drug Designation for JUV-161 for the Treatment of Myotonic Dystrophy Type 1Read More »

January, 2024

Juvena Therapeutics is recognized in Biospace’s Top 30 list, “NextGen Class of 2024: Top Life Sciences Startups to Watch This Year”Read More »

January, 2024

CEO Dr. Yousef speaks about “The Science of Longevity: Stopping Aging at the Cellular Level to Prevent Disease and Improve Quality of Life” as an invited panelist for the 2023 Biotech Showcase.Read More »

November, 2023

Juvena’s CEO, Dr. Hanadie Yousef is recognized by FierceBiotech in their 2023 shortlist of 10 of the fiercest women in life sciences.Read More »

October, 2023

Congratulations to our outstanding ML Engineer, Tejaswini Ganapathi for presenting a poster based on her AI research at Juvena entitled “Prediction of transcriptomic response to perturbagens in unobserved cell lines and cell states” at the ML Drug Discovery Symposium at Broad Institute of MIT and Harvard on October 27, 2023. We presented our exciting development of a generalized machine learning system that predicts biological effects such as gene expression changes on cells.Read More »

August, 2023

CEO Dr. Hanadie Yousef is recognized by Business Insider on their shortlist of 30 under 40 Transforming Healthcare Read More »

June, 2023

The Juvena team made a big splash at the 5th Age-Related Disease Therapeutics Summit in San Francisco! CEO, Dr. Hanadie Yousef gave a well received talk on mapping secreted proteins to unmet medical needs, as well as moderating the session of impressive speakers focused on biomarkers for age-related and chronic diseases. Juvena’s VP of Data Science, Dr. Eddie Moler co-led a pre-conference workshop on exploring the promise of AI-Powered drug discovery for the progression of age-related therapies, while Computational Biologist, Dr. Rohit Jadhav presented a poster on Juvena’s proteomics platform for mining the secretomes of stem cells. Read More »

May, 2023

Endpoints: CEO and co-Founder Dr. Hanadie Yousef is recognized by Endpoints for her lifelong scientific work and discoveries, for her entrepreneurship and business leadership as part of the 2023 “20 under 40” list of exceptional biotech leaders and global change makersRead More »

May, 2023

Juvena’s CEO and co-founder, Dr. Hanadie Yousef, was named among a distinguished short list of Emerging Pharma Leaders by Pharmaceutical Executive, which highlights her personal story and what drives Dr. Yousef’s passion for decoding secreted proteins for better human healthRead More »

March, 2023

CEO Dr. Yousef joins the Biotech CEO sisterhood summit to cultivate a community of support for female-led biotech companies and mentorship. Discussions included CEO best practices, wellness, supporting women leaders, and board service.  Learn more here where she is quoted.Read More »

January, 2023

Biocom highlights backgrounds of Catalyst Award winners including CEO Hanadie YousefRead More »

January, 2023

As Juvena continues to welcome a tremendously talented team, we wanted to thank FierceBiotech, Endpoints News, STAT, Longevity.Technology, BioWorld, and BioCentury for highlighting Juvena Therapeutics’ expanded leadership team last week. Juvena is thrilled to have Neil Berkley as Chief corporate development officer, Mo Tabrizi PhD, RPh as VP of preclinical and non-clinical development, and Edward Moler, PhD as VP of data science. Juvena is looking forward to what’s ahead!Read More »

January, 2023

BioWorld Features Dr. Yousef’s and Dr. O’Connell’s founding story, showcasing Juvena’s proteomics platform to tackle chronic and age-related diseases by mining hESC-secreted proteinsRead More »

January, 2023

Juvena Therapeutics Bolsters Leadership Team With Key Industry Veterans in Drug Discovery and Development, Data Science, and Business DevelopmentRead More »

January, 2023

National Institute of Aging showcases Juvena TherapeuticsRead More »

December, 2022

Longevity Technology Spotlights the Early Beginnings and Future Vision of Juvena TherapeuticsRead More »

November, 2022

The Wall Street Journal Discusses Juvena’s Series A and Its Potential to Expand the Range of Treatments for Chronic Conditions and Disease of AgingRead More »

November, 2022

Juvena Secures $41 Million to Accelerate the Discovery and Development of Biologics for Chronic and Age-Related DiseasesRead More »

October, 2022

BioCom California, the leading life science industry organization in California recognizes Juvena’s CEO, Dr. Hanadie Yousef for her achievements, vision and scientific and business accumen in its Life Science Catalyst Awards.Read More »

February, 2022

Juvena Therapeutics Awarded Highly Competitive 3.9M CIRM TRAN1 Grant to Advance Lead Program, JUV-161, to Treat Myotonic Dystrophy Type 1Read More »

November, 2021

CIRM Awards Juvena a $3.9M TRAN1 Grant to Advance JUV-161 for Myotonic Dystrophy Type 1 (DM1)Read More »

February, 2020

Juvena Therapeutics Interviewed– Embryonic Proteins for Tissue Regeneration- Jan 2020Read More »

January, 2020

Juvena Therapeutics Listed as 1 of 3 Ground Breaking Longevity StartupsRead More »

October, 2019

Dr. Hanadie Yousef’s Entrepreneurship Recognized by Spark at StanfordRead More »

May, 2019

CEO Hanadie Yousef’s Most Recent Publication in Nature MedicineRead More »

March, 2019

Medium Blog Parameter Mentions Juvena TherapeuticsRead More »

March, 2019

Juvena Therapeutics Mentioned in ForbesRead More »

July, 2018

Juvena Therapeutics Mentioned in Middle Market GrowthRead More »

January, 2017

Antibody Can Protect Brains From the Ageing Effects of Old BloodRead More »

July, 2016

Hanadie Yousef, Cofounder and CEO, in Scope by Stanford MedicineRead More »

May, 2016

The Bloody Battle Against AgingRead More »

June, 2015

Featured in Vice: Engineering the End of AgingRead More »

May, 2015

CEO Highlighted in the Daily CalifornianRead More »

Publications

June, 2024

Dr. Jeremy O’Connell, Director of translation Dr. Priya Handa, and Scientist Dr. Ritwik Datta attend and present our latest results at ENDO 2024, highlighting how  JUV-112 Offers a Distinctive Approach to Weight Loss and Metabolic HealthRead More »

May, 2024

InVivo spotlights CEO and Co-Founder Dr. Hanadie Yousef’s Journey with Juvena TherapeuticsRead More »

March, 2024

Ashil Koranne presented a poster at the 2024 MDA Clinical & Scientific Conference highlighting Juvena Therapeutics’ promising preclinical development of JUV-161, a novel fusion protein for treating Myotonic Dystrophy Type 1.Read More »

October, 2023

Congratulations to our outstanding ML Engineer, Tejaswini Ganapathi for presenting a poster based on her AI research at Juvena entitled “Prediction of transcriptomic response to perturbagens in unobserved cell lines and cell states” at the ML Drug Discovery Symposium at Broad Institute of MIT and Harvard on October 27, 2023. We presented our exciting development of a generalized machine learning system that predicts biological effects such as gene expression changes on cells.Read More »

September, 2023

National Institute on Aging Spotlights our CEO’s scientific journey and Juvena Therapeutics mission to unlock the secrets of tissue regenerationRead More »

September, 2023

Juvena’s CSO, Dr. Jeremy O’Connell, and VP Dr. Mo Tabrizi attend and present, both through oral presentation and poster, our DM1 lead program at the annual Myotonic Dystrophy Foundation Conference which we are proud to sponsorRead More »

September, 2023

Our Director of Discovery and Platform, Dr. Thach Mai and CSO Dr. Jeremy O’Connell share more about Juvena’s discovery platform and approach to identifying and developing a regenerative biologics for promoting lung epithelium re-growth for the treatment of idiopathic pulmonary fibrosis at the IPF 2023 Annual summit.Read More »

June, 2023

The Juvena team made a big splash at the 5th Age-Related Disease Therapeutics Summit in San Francisco! CEO, Dr. Hanadie Yousef gave a well received talk on mapping secreted proteins to unmet medical needs, as well as moderating the session of impressive speakers focused on biomarkers for age-related and chronic diseases. Juvena’s VP of Data Science, Dr. Eddie Moler co-led a pre-conference workshop on exploring the promise of AI-Powered drug discovery for the progression of age-related therapies, while Computational Biologist, Dr. Rohit Jadhav presented a poster on Juvena’s proteomics platform for mining the secretomes of stem cells. Read More »

March, 2020

CEO Hanadie Yousef Publishes in Cell ReportsRead More »

January, 2020

Co-founders, Dr. Hanadie Yousef and Dr. Jeremy O’Connell were invited speakers at the 2nd Annual Longevity Conference in SF. While Yousef gave an oral presentation, O’Connell presented a poster about Juvena’s quantitative proteomics approach for mining the secretome of human pluripotent stem cells.Read More »

July, 2019

CEO Hanadie Yousef’s Nature Paper Featured in Science Signaling as Editors ChoiceRead More »

Videos

April, 2024

Jeremy O’Connell presents video discussing JUV-161 for myotonic dystrophy type 1 (DM1)Watch Now »

August, 2023

EARD 2023 Panel, “Is Aging Truly Reversible” Featuring CEO Dr. Hanadie YousefWatch Now »

December, 2022

Juvena’a CEO, Dr. Hanadie Yousef discusses “Harnessing the Regenerative Secretome of Human Pluripotent Stem Cells” with other industry leaders discussing key areas of innovation advancing human healthspan and longevity at the Second Annual Longevity SummitWatch Now »

November, 2022

Annual BioFuture 2022 Event Recognizes Juvena CEO Dr. Hanadie Yousef Among Longevity Pioneers Shaping Expectations in Healthcare and Celebrates the Company’s Series A AnnouncementWatch Now »

August, 2022

EARD 2022: Mapping Secreted Proteins to Unmet Medical Needs by Dr. Thach Mai at Juvena August 2022Watch Now »

Hanadie-served-on-a-CEO-panel-with-a-group-of-portfolio-companies-for-Bascom-Ventures--thumbs

December, 2021

Hanadie served on a CEO panel with a group of portfolio companies for Bascom Ventures (part of Alumni Ventures)Watch Now »

CEO-Dr.-Yousef-Represents-Juvena-at-Longevity-Summit-2021-Thumb

November, 2021

CEO Dr. Yousef Represents Juvena at Longevity Summit 2021Watch Now »

CEO-Dr.-Yousef-Represents-Juvena-at-Metabesity-2021-thumb

October, 2021

CEO Dr. Yousef Represents Juvena at Metabesity 2021Watch Now »

August, 2021

CEO Dr. Hanadie Yousef is interviewed by Ira Pastor for his Progress, Potential, and Possibilities show on Juvena’s development of Secretome Derived TherapiesWatch Now »

Juvena-Therapeutics-Presents-at-the-Muscular-Dystrophy-Association-Insights-in-Research-Investor-Summit-thumb

April, 2021

Juvena Therapeutics Presents at the Muscular Dystrophy Association Insights in Research Investor SummitWatch Now »

Juvena-Therapeutics-Interviewed-by-Fortune-Jan.-2021-thumb

February, 2021

Juvena Therapeutics Interviewed by Fortune Jan. 2021Watch Now »

Juvena-Therapeutics-Presents-at-the-International-Longevity-Alliance-Conference-Workshop-Feb-2021-thumb

February, 2021

Juvena Therapeutics Presents at the International Longevity Alliance Conference Workshop Feb 2021Watch Now »

Juvena-Therapeutics-at-Metabesity-Oct-2020-Conference-thumb

October, 2020

Juvena Therapeutics at Metabesity Oct 2020 ConferenceWatch Now »

Ending-Age-Related-Diseases-Conference-August-2020-thumb

August, 2020

Ending Age-Related Diseases Conference August 2020Watch Now »

Podcasts

April, 2024

One of In Vivo’s 2024 Rising Leaders, Dr. Hanadie Yousef, CEO of Juvena Therapeutics, talks about the secretome as a source of therapeutics, the company’s lead assets, the future of longevity medicine and learning as you go as a biotech entrepreneur.Listen Now »

June, 2023

Discovery of Biologic Therapeutics in the AI/ML Era: 20-year industry veteran and Vice President of Data Science, Dr. Edward Moler, PhD, shares his insights on navigating AI-driven discoveries with high therapeutic potentialListen Now »

May, 2023

Check out the Pharma Exec Podcast of CEO Dr. Hanadie Yousef’s interview for the Emerging Pharma Leader award to learn more about what drives her ambitions for JuvenaListen Now »

January, 2023

Juvena’s Head of Data Science, Dr. Eddie Moler interviewed about his experiences in data science and AI applied to diagnostics and drug discovery and shares why he is excited about JuvenaListen Now »

CEO-Dr.-Hanadie-Yousef-Interviewed-for-Translating-Aging-PodcastThe-Cures-Within-Us-thumb

August, 2021

CEO Dr. Hanadie Yousef Interviewed for Translating Aging Podcast, “The Cures Within Us”Listen Now »

Events

June, 2024

CEO. Dr. Hanadie Yousef participates in AFAR’s webinar on AI + Longevity Drug DiscoveryLearn More »

June, 2024

CEO Dr. Hanadie Yousef gives a talk on Juvena’s AI-enabled protein drug discovery and development platform and lead therapeutic candidates for muscle regeneration and enhancing fat metabolism at the Longevity Summit DublinLearn More »

June, 2024

CEO Dr. Hanadie Yousef represents Juvena on 2 panels at BIO San Diego to discuss navigating the frontiers of First-in-Class therapeutics, and how healthspan promoting therapeutics are entering the biopharma mainstream.Learn More »

June, 2024

CEO Dr. Hanadie Yousef represents Juvena on 2 panels at BIO San Diego to discuss navigating the frontiers of First-in-Class therapeutics, and how healthspan promoting therapeutics are entering the biopharma mainstream.Learn More »

June, 2024

Juvena’s SVP of Translation, Dr. Mo Tabrizi participates in the Seattle Myotonic Dystrophy Regional Summit, where Juvena gave an industry presentation.Learn More »

May, 2024

Juvena’s CEO Dr. Hanadie Yousef participates in the LA Myotonic Dystrophy Regional Summit, where Juvena gave an industry presentation.Learn More »

May, 2024

Juvena’s Director of Discovery & Platform, Dr. Thach Mai presents “Mapping the therapeutic potential of secreted proteins through integrating AI and quantitative multi-omics technology” at the Element Biosciences RoadshowLearn More »

November, 2023

CEO Dr. Hanadie Yousef discussed the convergence of AI, healthcare, and longevity in early November in Paris at JPM 40×40 as an invited speaker amongst a curated group of global business leaders across all sectors.Learn More »

November, 2023

Dr. Hanadie Yousef attends the Global Healthspan Summit in Riyadh, Saudi Arabia, organized by the Hevolution Summit as an invited speaker showcased on their Entrepreneurship Spotlight panelLearn More »

October, 2023

CEO, Dr. Yousef presented Juvena’s approach to mining the regenerative secretomes of human pluripotent stem cells to identify and develop novel disease-modifying biologics that promote tissue regeneration and repair in order to rejuvenate lives as the 14th annual drug discovery strategic summit this year.Learn More »

October, 2023

Congratulations to Juvena Therapeutics Co-Founder and CEO Dr. Yousef for being named a “Big Think” speaker at #BioFuture2023 in recognition of the company’s accelerated growth and momentum in addressing a long-standing critical gap in drug discovery by unlocking the therapeutic potential of secreted proteins in order to develop regenerative therapeutics.Learn More »

September, 2023

Our Director of Discovery and Platform, Dr. Thach Mai and CSO Dr. Jeremy O’Connell share more about Juvena’s discovery platform and approach to identifying and developing a regenerative biologics for promoting lung epithelium re-growth for the treatment of idiopathic pulmonary fibrosis at the IPF 2023 Annual summit.Learn More »

September, 2023

Juvena is delighted to have had the opportunity to participate in the Mubadala Capital Singapore Forum. CEO Dr. Yousef was on the panel, “The New Frontier of Biotech Investing & Company Creation”Learn More »

September, 2023

Juvena’s CSO, Dr. Jeremy O’Connell, and VP Dr. Mo Tabrizi attend and present our DM1 lead program at the annual Myotonic Dystrophy Foundation Conference which we are proud to sponsorLearn More »

July, 2023

Excited to announce Juvena’s CEO, Dr. Yousef’s participation at the Longevity Summit: Ending Age-Related Diseases in NYC on August 10-11! Join her and other experts as we revolutionize the field of aging research. Learn more and register hereLearn More »

July, 2023

Wu Xi Apptec spotlights Juvena Therapeutics on their Spotlight III: “The Next Wave of Rare Disease Therapeutics” episode. Our CEO, Dr. Yousef discusses Juvena’s unique approach to developing innovative disease-modifying biologics for chronic and rare degenerative diseases by mapping the therapeutic potential of secreted proteins. Learn more and register for the July 27 episode here.Learn More »

December, 2022

Juvena’a CEO, Dr. Hanadie Yousef discusses “Harnessing the Regenerative Secretome of Human Pluripotent Stem Cells” with other industry leaders discussing key areas of innovation advancing human healthspan and longevity at the Second Annual Longevity SummitLearn More »

November, 2022

Juvena’s lead drug discovery Scientist, Dr. Thach Mai, gave an excellent lecture, “Mapping Secreted Proteins to Unmet Medical Needs” to graduate students at Maastricht Centre for Systems Biology (MaCSBio).  Dr. Mai outlined Juvena’s use of machine learning and computational tools to unravel the therapeutic potential of stem cell-secreted human proteinsLearn More »

November, 2022

Stanford University welcomed CEO Dr. Hanadie Yousef as a guest lecturer to share her journey in launching Juvena TherapeuticsLearn More »

November, 2022

Juvena CEO, Hanadie Yousef, Explores the Future of the Intersection of Technology and Biology Alongside Silicon Valley Entrepreneurs with Middle East & Northern African roots at the Annual TechWadi ForumLearn More »

November, 2022

Biocom California Names Juvena CEO Hanadie Yousef as One of Ten Recipients of Its 7th Annual Catalyst Award, Recognizing the Most Inspiring and Driven Minds Sparking Meaningful Change to Human HealthLearn More »

November, 2022

Discussing longevity insights among financial and biotech leaders at the BioFuture Conference, Juvena CEO, Hanadie Yousef, PhD explores the role of secreted proteins in targeting chronic and age-related diseases.Learn More »

November, 2022

Juvena’s CSO, Dr. O’Connell, was an invited speaker at the 6th Annual Fibrotic Drug Discovery Summit in Nov. 2022 and discussed how decoding stem cell secreted proteins can enable drug discovery for fibrotic degenerative diseases, providing an overview of Juvena’s pulmonary and hepatic programs.Learn More »

November, 2022

Annual BioFuture 2022 Event Recognizes Juvena CEO Dr. Hanadie Yousef Among Longevity Pioneers Shaping Expectations in Healthcare and Celebrates the Company’s Series A AnnouncementLearn More »

November, 2022

Juvena Therapeutics is recognized for its transformative science that targets unmet medical needs as well as for the quality of its management team as part of the Emerging Company Showcase at the prestigious Life Sciences Summit.Learn More »

October, 2022

Juvena CEO, Hanadie Yousef, PhD, discusses the market opportunity for their unique discovery platform for mapping secreted proteins to unmet medical needs leading to their growing pipeline of biologics for rare and chronic diseases to senior leaders of Mubadala’s LP.Learn More »

October, 2022

To help drive change in biotech, Dr. Hanadie Yousef joined the industry’s leading women CEOs and investors at  the first joint Women Investors and CEOs networking event hosted by Sofinnova Investments and Cowen. Together these women are driven to create positive change in the industry, improving diversity among biotech c-suite and investors and supporting one another.Learn More »

September, 2022

Horizon Ventures Techcracker conference spotlights Juvena Co-Founder, Hanadie Yousef, PhD as one of 70 founders of innovative new companies developing disruptive technologies that improve lives Oct. 2022Learn More »

September, 2022

At the Myotonic Dystrophy Foundation Annual conference Juvena Therapeutics joins a community of advocates, people who suffer from this most common muscular dystrophy, their families, caregivers, clinical leaders and experts, and Industry leaders developing therapeutics for this major unmet medical need Sept. 2022Learn More »

August, 2022

The Ending Age-Related Diseases Conference Featured Juvena CEO and CO-Founder, Hanadie Yousef, PhD, as a leading aging biology expert discussing “Building a Pipeline of Therapeutics that Target Diseases of Aging” and Dr. Thach Mai, leading Discovery Scientist, discussing Juvena’s innovative ML-enhanced platform for protein drug discovery Aug. 2022Learn More »

July, 2022

CSO and Co-Founder Dr. Jeremy O’Connell presents at FASEB Industry Panel Jul. 2022Learn More »

June, 2022

CEO Hanadie Yousef was honored to represent Juvena Therapeutics at BIO International Convention in June 2022, where she gave a Company Presentation at the emerging company showcase. She had numerous meetings with exciting companies and investors focused on partnerships and was all around inspired by the exceptional attendees, sponsors, and organizers. Thanks to The National Institutes of Health for sponsoring the Innovation Zone and Juvena’s attendanceLearn More »

November, 2019

CEO Dr. Hanadie Yousef Presents at UC Berkeley’s Slam Seminar Series Nov. 2019Learn More »

juvena-logo-wht

Navigation

Contact

640 Galveston Drive
Redwood City, CA 94063
Get Directions »
650.223.5879
[email protected]

Stay in touch

Subscribe to our newsletter

By entering your email you agree to our Privacy Policy

© 2023 Juvena Therapeutics Inc. All Rights Reserved | Privacy Policy